Actively Recruiting
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-03-02
240
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in elderly patients (aged 55-75) with acute myeloid leukemia (AML) who are fit for intensive chemotherapy.
CONDITIONS
Official Title
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of acute myeloid leukemia (AML) according to WHO (2022) or ICC criteria
- Age between 55 and 75 years
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- Adequate organ function including total bilirubin up to 1.5 times upper limit of normal, AST and ALT up to 2.5 times upper limit, serum creatinine less than 2 times upper limit, cardiac enzymes less than 2 times upper limit, and normal left ventricular ejection fraction (LVEF) by echocardiogram
- Signed informed consent by the patient or legal representative
You will not qualify if you...
- Acute promyelocytic leukemia with PML-RARA fusion gene
- AML with RUNX1-RUNX1T1 or CBFB-MYH11 fusion genes
- AML with BCR-ABL fusion gene
- Relapsed or refractory AML previously treated with induction chemotherapy (hydroxyurea allowed)
- Concurrent other malignancies requiring treatment
- Active cardiac disease such as uncontrolled angina, recent myocardial infarction, severe arrhythmias, uncontrolled heart failure, or LVEF below normal
- Severe infectious diseases including untreated tuberculosis or pulmonary aspergillosis
- Other conditions considered unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Blood Diseases Hospital
Tianjin, China
Actively Recruiting
Research Team
H
Hui Wei, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here